Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephanos Finitsis has a total of 362 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Peroneus brevis tenosynovitis associated with hypertrophied peroneal tubercle: Comparative analysis of 2 cases and their etiologies

    by Antonios Michailidis, Ioannis Tsifountoudis, Dimitrios Kitridis, George Paparoidamis, Konstantinos Tasoulis, Danae Makri, Evangelos Petsatodis, Stefanos Finitsis

  • Open Access

    Limitations and Blind Spots of Diffusion-Weighted Imaging in the Evaluation of Acute Brain Ischemia: A Narrative Review

    by Ioannis Nikolakakis, Ioanna Koutroulou, Michail Mantatzis, Stefanos Finitsis, Nikolaos Grigoriadis, Theodoros Karapanayiotides

    Diffusion-weighted imaging (DWI) has been increasingly utilized in the emergent evaluation of acute ischemic stroke (AIS) patients. DWI enhances sensitivity and specificity and enables the use of delayed reperfusion treatments in selected cases. However, DWI is not devoid of limitations. DWI-negative AIS is not uncommon in clinical practice and is reported in up to 1 of 4 AIS patients. We reviewed the relevant literature and searched the PubMed and Google Scholar databases for studies reporting on DWI-negative AIS prevalence during the 2021–2025 time period. Additionally, we included cases from our practice to highlight key points. DWI-negative AIS prevalence was 16% in one meta-analysis and ranged from 6.9% to 23.2% in identified studies that met our inclusion criteria. The biological, pathophysiological, technical, epidemiological and clinical factors that contribute to DWI-negative stroke are presented in detail. Overall, the application of diffusion imaging modalities for stroke is not bereft of blind spots despite enhanced sensitivity. Over-reliance on advanced neuroimaging and unfamiliarity with its limitations predispose DWI to errors in AIS assessment. Awareness of the predisposing factors, treatment effect, and prognosis guides appropriate decision-making, promoting good outcomes. Prospective appropriately designed trials should address the lingering questions identified, such as the association between time of imaging and DWI negativity.


  • Evaluation of the INCISIVE Services in Cancer Imaging: A Feasibility Study

    by Lithin Zacharias, Iman Hesso, Reem Kayyali, Andreas Charalambous, Elizabeth Katherine Anna Triumbari, Ioanna Chouvarda, Tatjana Loncar-Turukalo, Stavros Sykiotis, Chrysostomos Symvoulidis, Alberto Gutierrez-Torre, et al.

  • Open Access

    Limitations and Blind Spots of Diffusion-Weighted Imaging in the Evaluation of Acute Brain Ischemia: A Narrative Review

    by Ioannis Nikolakakis, Ioanna Koutroulou, Michail Mantatzis, Stefanos Finitsis, Nikolaos Grigoriadis, Theodoros Karapanayiotides

    Diffusion-weighted imaging (DWI) has been increasingly utilized in the emergent evaluation of acute ischemic stroke (AIS). DWI enhances the sensitivity of diagnosis and enables the use of delayed reperfusion treatments in selected cases. However, DWI is not without limitations. DWI-negative AIS may be encountered in up to 1 out of 4 patients with minor stroke. We searched PubMed and Google Scholar for studies reporting on the prevalence of DWI-negative AIS from 2021 to 2025 and we extensively reviewed the relevant literature. Additionally, we included cases from our practice to highlight key points. DWI-negative AIS prevalence was 16% in one meta-analysis and ranged from 6,9% to 23,2% in identified studies that met our inclusion criteria. Biological, pathophysiological, technical, epidemiological and clinical factors that contribute to DWI-negative stroke are presented in detail. Overall, the application of diffusion imaging modalities in stroke is not bereft of blind spots despite enhanced sensitivity. Over-reliance on advanced neuroimaging and unfamiliarity with limitations predispose to errors in AIS assessment. Awareness about predisposing factors, treatment effect and prognosis guides appropriate decision-making, promoting good outcomes. Prospective appropriately-designed trials should address crucial issues such as the association between timing of imaging and DWI negativity.

  • Open Access

    Electrochemotherapy in the Management of Vascular Malformations: An Updated Systematic Review

    by Antonios Michailidis, Ioannis Tsifountoudis, Evangelos Perdikakis, Georgios Fragkos, Ola Furmaga-Rokou, Prodromos Koutoukoglou, Danae Makri, Evangelos Petsatodis, Stefanos Finitsis

    Background: Vascular malformations (VMs) are congenital anomalies of the vascular system—capillary, venous, lymphatic, arteriovenous, or combined—frequently associated with notable morbidity and reduced quality of life. Electrochemotherapy (ECT), a locoregional treatment that combines chemotherapeutic agents (most commonly bleomycin) with electroporation, has emerged as a promising alternative in managing therapy-resistant or anatomically challenging lesions. Methods: A systematic review of the literature was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, Embase, and the Cochrane Library were searched from inception to January 2025 for studies reporting on the efficacy and/or safety of ECT for vascular malformations. Data extraction encompassed study design, patient demographics, VM type, ECT protocols, outcomes, follow-up duration, and adverse events. Studies that lacked relevant outcome data or focused solely on other therapeutic approaches were excluded. Results: Twelve primary studies met the inclusion criteria and were analyzed. These covered diverse VMs, including venous, slow-flow, high-flow malformations, aggressive hemangiomas, and composite lesions in adult and pediatric populations. ECT protocols usually combined bleomycin (or occasionally other agents such as pingyangmycin or polidocanol foam) with various electroporation parameters. Across studies, ECT resulted in meaningful lesion-size reduction (50–97% in most cohorts), symptom relief (e.g., reduced pain and bleeding), and favorable cosmetic outcomes. While side effects (local edema, hyperpigmentation, procedure-related discomfort) were occasionally reported, they were typically mild and transient. Conclusions: ECT represents a valuable minimally invasive option in the therapeutic armamentarium for vascular malformations. Despite consistent demonstrations of efficacy and acceptable toxicity profiles, future high-quality, multicenter studies are warranted to confirm outcomes, refine treatment guidelines, and potentially expand its use as a standard of care.


  • MRA evaluation of aneurysms treated with woven endobridge (WEB) devices or coils: an inter- and intra-observer reliability study

    by Pierre-Olivier Comby, Tim E. Darsaut, Anass Benomar, Daniela Iancu, Daniel Roy, Roland Jabre, Alain Weill, Nicolas Lecaros, Hanan Alhazmi, Francois Zhu, et al.

    Background Magnetic resonance angiography (MRA) is a commonly used non-invasive imaging modality for the follow-up of treated intracranial aneurysms. The 3-category Montreal classification system is widely used to evaluate treatment outcomes, including aneurysms treated with Woven EndoBridge (WEB) devices or coils. This study aimed to assess the reliability and clinical implications of the Montreal scale for aneurysms imaged with MRA. Methods An electronic portfolio of 60 aneurysms (30 treated with WEB devices and 30 with coils) was evaluated by 30 raters from diverse clinical backgrounds. Raters graded aneurysm occlusion using the Montreal classification system and provided management recommendations (delayed follow-up, close follow-up, or re-treatment). Twenty-three raters completed a second evaluation of permuted cases after one month. Reliability was assessed using Gwet’s AC2 (κG) coefficients, and the correlation between occlusion grade and management recommendation was analyzed with Cramer’s V. Results Inter-rater agreement for occlusion grades was substantial (κG = 0.70; 95% CI: 0.66–0.75) and similar for WEB-treated (κG = 0.66; 95% CI: 0.59–0.74) and coiled aneurysms (κG = 0.75; 95% CI: 0.68–0.82). Management decisions showed substantial agreement overall (κG = 0.68; 95% CI: 0.60–0.76). Mean intra-rater agreement was almost perfect (κG = 0.84 ± 0.06). Strong correlations were observed between occlusion grades and management recommendations (mean Cramer’s V = 0.78 ± 0.13), with consistent management strategies across treatment modalities. Conclusion The Montreal scale demonstrated substantial reliability and clinical relevance for evaluating aneurysms treated with WEB or coils using MRA, supporting its use in non-invasive follow-up protocols.

  • Rescue intracranial stenting for failed mechanical thrombectomy of vertebrobasilar occlusions: a pooled analysis from the French and German national stroke registries

    by Victoria Lambrou, Sven Poli, Bertrand Lapergue, Joshua Mbroh, Xinchen Hui, Florian Hennersdorf, Ulrike Ernemann, Marek Sykora, Daniel Strbian, Sébastien Richard, et al.

    Background Whether rescue intracranial stenting (RIS) should be performed in patients with vertebrobasilar occlusions (VBO) refractory to endovascular mechanical thrombectomy (MT) remains an open question. Methods We conducted a pooled analysis using data from two national stroke registries, the Endovascular Treatment in Ischemic Stroke registry in France, and the German Stroke Registry–Endovascular Treatment. Patients with VBO who underwent RIS for failed MT, defined as a modified treatment in cerebral infarction (mTICI) score of 0 to 2a after MT, from January 2015 to December 2023 were included. The primary outcome was a modified Rankin Scale (mRS) score of 0–3 at 90 days. Secondary outcomes included mRS distribution and mortality at 90 days, any intracranial hemorrhage (ICH) and symptomatic intracranial hemorrhage (sICH). Propensity score matching and inverse propensity weighting were employed to balance baseline differences. Results Among 2028 patients, 307 (15.1%) patients had MT-refractory VBO. Of these, 127 (41.4%) underwent RIS and 180 (58.6%) patients no RIS. After propensity score matching, two balanced groups were obtained: 106 patients with RIS and 99 without RIS. Patients who underwent RIS had higher odds of achieving an mRS 0–3 (adjusted odds ratio (aOR) 3.45, 95% confidence interval (CI) 1.27 to 9.34. P=0.014), a favorable shift across the mRS distribution (aOR 2.55 per 1-point mRS improvement, 95% CI 1.22 to 5.34; P=0.013) and lower odds of 90-day mortality (aOR 0.26, 95% CI 0.09 to 0.71; P=0.008). There were no significant differences in any ICH and sICH. Conclusion This registry-based study provides level 3 evidence supporting the use of RIS in patients with VBO refractory to MT. Prospective randomized trials are necessary to validate the potential benefits of RIS in this condition.


  • Stent retriever size and outcomes after anterior circulation occlusion thrombectomy

    by Benjamin Gory, Sven Poli, Bertrand Lapergue, Stephanos Finitsis, Joshua Mbroh, Xinchen Hui, Florian Hennersdorf, Ulrike Ernemann, Mohammad Anadani

    Background The impact of stent retriever size on mechanical thrombectomy (MT) outcomes remains uncertain. We aim to clarify the influence of stent retriever size on MT outcomes by analyzing data from two national prospective registries. Methods A retrospective analysis was performed on data from the French and German MT registries including consecutive patients with anterior circulation large vessel occlusion who underwent Solitaire stent retriever MT with or without additional aspiration. Efficacy outcomes were successful reperfusion and complete reperfusion. Safety outcomes included any intracerebral hemorrhage (ICH) and symptomatic intracerebral hemorrhage (sICH). Results Complete reperfusion was lower in the 4×20 mm stent retriever group than in the 4×40 mm stent retriever group (47% vs 53%; OR 0.61, P=0.0039). Successful reperfusion did not differ between the 4×20 mm and 4×40 mm stent retriever groups (89% vs 93%; OR 0.69, P=0.25). There was no difference between the 6×30/6×40 mm and 4×20 mm stents, and there was no difference in functional outcomes between the groups. In terms of safety, any ICH was lower in the 4×20 mm group than in the 4×40 mm group (20% vs 36%; OR 0.60, P=0.0095). Symptomatic ICH was lower in the 4×20 mm group than in the 4×40 mm group (5% vs 10%; OR 0.58, P=0.086), but the difference did not reach statistical significance. Mortality was lower in the 4×20 mm than in the 6×40 mm group (26% vs 33%; OR 0.70, P=0.044). When compared according to occlusion location, the results were overall similar. Conclusion This study suggests that longer and larger stent retrievers lead to a higher reperfusion rate but also a higher rate of hemorrhagic complications. Overall, the size of the stent did not affect functional outcomes.


  • Reliability and applicability of angiographic outcome scales in WEB device-treated aneurysms: a systematic review

    by Pierre-Olivier Comby, Stefanos Finitsis, Daniela Iancu, Maria Alexandratou, Anass Benomar, Daniel Roy, Alain Weill, Roland Jabre, Nicolas Lecaros, Hanan Alhazmi, et al.

    Purpose Various angiographic assessment scales have been used to report the results of endovascular treatment with the WEB device. We aimed to review the use and reliability of these scales. Methods We systematically reviewed studies reporting angiographic outcomes of WEB-treated aneurysms from January 2010 to May 2023. We identified the studies that reported the reliability of the various scales. Data from eligible studies were extracted and evaluated by two independent reviewers, with discrepancies resolved by a third reviewer. Findings The review identified 138 studies that used 12 different occlusion scales. The non-specific Raymond-Roy occlusion classification (RROC) was most commonly used (94/138 (68%)), followed by the Bicêtre Occlusion Scale Score (BOSS; 21/138 (15%)) and the Web Occlusion Scale (WOS; 16/138 (12%)), both specifically adapted to the WEB. Six reliability studies were identified, which included 16–30 cases evaluated by few (2–7) raters. Studies were too heterogenous to proceed with a meta-analysis. Substantial agreement in reporting angiographic results was shown in one study using the WOS (K = 0.70; 0.64–0.75), and one using the BOSS (K = 0.82; 0.68–0.96), but only when categories were dichotomized as complete versus incomplete occlusion. Most classifications can be translated into the RROC, allowing comparisons with other devices and treatment modalities. The RROC reached substantial agreement, but only between 2 raters in a small 26-patient study (k = 0.69; 0.46–0.93). Conclusion More agreement studies are needed to validate the reliability of angiographic outcome scales that can be used to compare WEB with other endovascular or surgical treatments.


  • Impact of time from symptom onset to puncture, and puncture to reperfusion, in endovascular therapy in the late time window (>6 h)

    by Agathe Sadeler, Stephanos Finitsis, Jean-Marc Olivot, Sebastien Richard, Gaultier Marnat, Igor Sibon, Lionel Calviere, Christophe Cognard, Mikael Mazighi, Jean-Philippe Desilles, et al.

    Background: Increased time from symptom onset to puncture (TSOP) and time from puncture to reperfusion (TPTR) are associated with worse outcome in ischemic stroke patients treated with endovascular therapy (EVT) in the early time window (6 h), where patients may benefit from EVT because of a more favorable imaging profile (late window paradox). We sought to compare the effect of these timeframes between these two periods on efficacy and safety outcomes. Methods: The ETIS (Endovascular Treatment in Ischemic Stroke) registry is an ongoing, prospective, observational study in 21 centers that perform EVT in France. We included adult patients with an anterior occlusion, successfully treated by EVT (modified treatment in cerebral ischemia (mTICI) 2b–3) between January 2015 and June 2023, with a known time of stroke onset. The cohort was divided into two groups according to the TSOP (⩽6 h vs >6 h). Primary outcome was favorable outcome (modified Rankin Scale 0–2 at 90 days). Results: In total, 7516 patients were included, with 5936 patients being treated ⩽6 h and 1580 >6 h. In the early window, TSOP and TPTR were associated with worse outcomes at 90 days (adjusted odds ratio (aOR) = 0.68 per hour; 95% confidence interval (CI) = 0.64–0.73; p < 0.001 and aOR = 0.92 per 10-min increment; 95% CI = 0.90–0.94, p < 0.001, respectively). TSOP was not associated with worse outcomes at 90 days in the late window ( p = 0.955), but TPTR was associated with worse outcomes (aOR = 0.91 per 10-min increment; 95% CI = 0.86–0.96, p = 0.001), every 10 additional minutes in TPTR being associated with a 1.7% (95% CI = 0.6–2.7) decreased probability of favorable outcome. Conclusion: Only EVT procedural time is associated with unfavorable outcomes at 90 days in late window patients. These results highlight how the late window paradox may end at the start of EVT and underscore the need for timely management, particularly for the EVT, even for late window patients with a presumed more favorable imaging profile.